Zobrazeno 1 - 7
of 7
pro vyhledávání: '"M Diaz Rangel"'
Autor:
B Serna Serrano, M Diaz Rangel, S Ruiz Sánchez, S Plata Paniagua, I Casas Hidalgo, F Sánchez Rubio, M Clemente Andújar, A Valladolid Walsh
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Ibrutinib is a potent Burton tyrosine kinase inhibitor involved in the proliferation and survival of chronic lymphatic leukaemia (CLL) B cells. This study was mainly motivated by suspensions for toxicity. Aim and objectives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58f32f7e00c13f22ec1296c8778844f7
https://doi.org/10.1136/ejhpharm-2021-eahpconf.124
https://doi.org/10.1136/ejhpharm-2021-eahpconf.124
Autor:
A Valladolid Walsh, J Marco del Rio, E Adrover Cebrian, F Sánchez Rubio, M Diaz Rangel, MV Lerma Gaude
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background The first-in-class oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) palbociclib, combined with hormonal therapy, is a new standard of treatment in the first and second line for hormone receptor-positive (HR+), human epidermal gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97925a71bd95976b8bb75ddd13d8cbcc
https://doi.org/10.1136/ejhpharm-2019-eahpconf.279
https://doi.org/10.1136/ejhpharm-2019-eahpconf.279
Autor:
A Valladolid Wals, F Bautista Sirvent, F Sánchez Rubio, M Diaz Rangel, G Romero Candel, J Marco del Rio, I Pérez Alpuente, N Martinez Monteagudo, V Lopez Martinez, E Domingo Chiva
Publikováno v:
Clinical pharmacy.
Background Medication errors and their severity represent a failure in the medication use process and can increase morbidity and mortality in the emergency department. Purpose To describe the types of medication errors (ME) and severity in the observ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8fbda66edce3b58e26a78af397463da
https://doi.org/10.1136/ejhpharm-2017-000640.131
https://doi.org/10.1136/ejhpharm-2017-000640.131
PS-065 Ivabradine prescription according to pharmacovigilance risk assessment committee restrictions
Autor:
A Valladolid Walsh, N Monteagudo Martínez, M Diaz Rangel, J Marco del Rio, E Domingo Chiva, G Romero Candel, S Plata Paniagua, F Sánchez Rubio, EM García Martínez, L Victorio García
Publikováno v:
European Journal of Hospital Pharmacy. 23:A242.1-A242
Background The Pharmacovigilance Risk Assessment Committee (PRAC) published restrictions on the use of ivabradine in 2014 for patients diagnosed with chronic stable angina pectoris (CSAP): begin treatment only if resting heart rate (HR) is >70 bpm, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6604097503f42da6e59c7edb76c6f8a4
https://doi.org/10.1136/ejhpharm-2016-000875.549
https://doi.org/10.1136/ejhpharm-2016-000875.549
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Diaz-Rangel M; Gerencia de Atencion Integrada de Albacete, Albacete, Espana., Grande-Martin A; Gerencia de Atencion Integrada de Albacete, Albacete, Espana., Monsalve-Naharro JA; Gerencia de Atencion Integrada de Albacete, Albacete, Espana., Domingo-Chiva E; Gerencia de Atencion Integrada de Albacete, Albacete, Espana., Cuesta-Montero P; Gerencia de Atencion Integrada de Albacete, Albacete, Espana., Lopez-Perez A; Gerencia de Atencion Integrada de Albacete, Albacete, Espana.
Publikováno v:
Revista de neurologia [Rev Neurol] 2017 Dec 16; Vol. 65 (12), pp. 574-575.